Autolus Therapeutics plc reports news on its commercial-stage biopharmaceutical business developing, manufacturing and delivering next-generation programmed T cell therapies. Updates center on AUCATZYL (obecabtagene autoleucel, or obe-cel), product revenue, manufacturing capacity, gross margin plans and the company’s acute lymphoblastic leukemia business.
Company announcements also cover clinical programs using obe-cel and related T cell therapy candidates in pediatric relapsed/refractory acute lymphoblastic leukemia, lupus nephritis and progressive multiple sclerosis. Other recurring items include financial results, operational efficiency actions, investor presentations, Nasdaq inducement equity grants and ADR-related public-company disclosures.
Autolus Therapeutics (Nasdaq: AUTL) announced a significant advancement in T-cell engineering with the publication of research that enhances CAR T-cell efficacy against solid tumors by preventing apoptosis caused by Fas ligand. The study, detailed in Molecular Therapy Nucleic Acids, highlights the development of Fas-TNFR chimeras that not only inhibit FasL-mediated cell death but also stimulate CAR T-cell proliferation. Among these, the Fas-CD40 fusion was noted for its effectiveness in improving anti-tumor response in FasL presence. This research expands Autolus' toolkit against complex cancers and aligns with its strategy to enhance T-cell therapy applications, particularly for solid tumors. The findings position Autolus as a key player in advancing cancer treatment through targeted therapies.
Autolus Therapeutics (Nasdaq: AUTL) announced positive updated data for its AUTO1/22 study in pediatric B-cell Acute Lymphoblastic Leukemia (B-ALL) at the 49th Annual Meeting of the European Society for Blood and Marrow Transplantation. The study demonstrated that AUTO1/22 effectively targets both CD19 and CD22 antigens, addressing CD19 negative relapse, a common treatment failure after CAR T cell therapy.
Among the 12 patients treated, 83% achieved minimal residual disease negative complete response, including 66.7% of patients with CD19 negative disease. Importantly, there were no severe cytokine release syndrome cases, and no relapses or emergence of minimal residual disease related to antigen escape were observed after a median follow-up of 8.7 months. This demonstrates the potential of AUTO1/22 in enhancing treatment efficacy and safety for pediatric B-ALL patients.
Autolus Therapeutics plc (Nasdaq: AUTL) will host a virtual Capital Markets Day on April 27, 2023, to discuss its lead CAR T program, obe-cel, aimed at treating adults with Acute Lymphoblastic Leukemia (ALL). The event will feature presentations and a Q&A session with experts, including Dr. Lori Muffly from Stanford University and Dr. Clare Roddie from University College London, along with Matthew Gitlin from Blue Path Solutions. The session, scheduled from 10 AM to 12 PM EDT (3 PM to 5 PM BST), is open to investors and analysts. Participants can register for the webcast here. A recording will also be available on the company’s website following the event.
Autolus Therapeutics plc (Nasdaq: AUTL) has announced that it will report its Q1 2023 financial results and operational highlights on May 4, 2023, before the U.S. market opens. Management will host a conference call at 8:30 am ET to discuss these results and provide a general business update. Interested participants can pre-register for the call to receive the necessary dial-in information. An audio webcast and replay will also be available on Autolus' website for those unable to attend the live event.
Autolus Therapeutics plc (NASDAQ: AUTL) announced the publication of a study in Molecular Therapy detailing AUTO1/22, a novel CAR T cell therapy targeting both CD19 and CD22 for treating B-cell Acute Lymphoblastic Leukemia (B-ALL). The study addresses the challenge of CD19 negative escape in pediatric patients, proposing a high-sensitivity CD22 CAR for better targeting. AUTO1/22 is currently in a pediatric clinical trial and aims to enhance outcomes for patients with B-ALL and potentially other B-cell malignancies. The development represents a significant advancement in the application's efficacy of Autolus' CD19 targeting platform.
Data Bridge Market Research's latest report highlights the global transfection reagent and equipment market, projected to reach USD 2,284,494.00 thousand by 2030, growing at a CAGR of 9.6% from 2023 to 2030. Key factors driving this growth include the rising prevalence of chronic diseases and the demand for gene therapy. The report outlines various applications of transfection methods, such as in immunotherapy and agriculture. However, challenges such as high instrument costs and selective reagent effectiveness may restrain market expansion. Notable developments include Mirus Bio's GMP platform expansion and BOC Sciences' RNA transfection kits.
Autolus Therapeutics (Nasdaq: AUTL) announced that Dr. Lucinda Crabtree will step down as Chief Financial Officer in Q3 2023 to pursue a new opportunity. A search for her replacement has begun, ensuring a smooth transition. Dr. Crabtree has played a key role in the company, which is at a pivotal moment with their CAR T cell therapy, obe-cel, achieving primary endpoint success in the FELIX study for adult ALL patients. Future presentations of comprehensive data are anticipated next quarter, providing insights into treatment benefits. The company expresses gratitude for Dr. Crabtree's contributions and optimism for its ongoing developments.
Autolus Therapeutics plc (Nasdaq: AUTL) has announced that it has no past or present business relationships with Silicon Valley Bank, following recent events concerning the bank. Autolus focuses on developing next-generation programmed T cell therapies for cancer treatment, utilizing proprietary T cell programming technologies. The company aims to create targeted, controlled, and effective therapies to combat cancer cells. Autolus is advancing its product pipeline for hematological malignancies and solid tumors, with ongoing clinical trials and a planned submission of a Biologics License Application for its obe-cel program by the end of 2023.
Autolus Therapeutics (AUTL) announced that its treatment, obe-cel, met the primary endpoint in the pivotal Phase 2 FELIX study for relapsed/refractory B-cell Acute Lymphoblastic Leukemia. The company plans to submit a Biologics License Application to the US FDA by year-end 2023, with data updates expected at a medical conference mid-2023. Financially, Autolus reported a net loss of $148.8 million for 2022, an increase from $142.1 million in 2021. Cash reserves stand at $382.8 million, bolstered by a successful fundraising of approximately $163.9 million. The company is positioned for a commercial launch of obe-cel in 2024.
The latest report on Chronic Lymphocytic Leukemia (CLL) market forecasts a robust pipeline of cell therapies, particularly CAR-T therapies, which are projected to capture significant market share by 2031. The report estimates the CLL cell therapy market will reach $2 billion in annual sales across major pharmaceutical markets, with overall CLL market sales peaking at $20.8 billion. The analysis covers the clinical landscape, unmet needs, and future players within the market, emphasizing a shift towards cell therapies for high-risk patients. The report spans 15 major markets, providing insights into disease epidemiology and forecast methodologies.